Clinical Research Directory
Browse clinical research sites, groups, and studies.
18F-FAPIBiotin PET/CT: Dosimetry and Biodistribution Study
Sponsor: First Affiliated Hospital of Fujian Medical University
Summary
As a new dual targeting PET radiotracer, 18F-FAPI-Biotin is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 18F-FAPI-Biotin in patients with various types of cancer and compared them with the results of 18F-FAPI or 18F-FDG imaging to evaluate the dosimetric characteristics and diagnostic efficacy of 18F-FAPI.
Official title: 18F-FAPIBiotin PET/CT: Dosimetry and Biodistribution Study in Patients With Various Cancers
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
5
Start Date
2024-06-25
Completion Date
2025-12-31
Last Updated
2024-12-16
Healthy Volunteers
No
Conditions
Interventions
18F-FAPIBiotin
The dose will be 148-296 MBq given intravenously.
Locations (1)
Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China